MORF: Morphic Therapeutic Company Value to Net Income

Symbol and logo of brand Morphic Holding Inc (MORF)

Morphic Holding, Inc. (MORF) relies on an asset-light structure, outsourcing all synthesis and tracking to external contractors. The company expects revenues from insurance reimbursements for oral IBD therapies. The price history on GURU.Markets shows a P/E multiple of -16.00, while internal capacities are focused on the development of integrin inhibitors under a distributed manufacturing model.

MORF Morphic P/E Multiple (07/04/2022 - 08/24/2024)

Analytical breakdowns for Morphic Holding, Inc.

- price and consensus price forecast:
Stock Price morphictx.com|MORF - Consensus Target
- market capitalization information:
Market Value Morphic Therapeutic|MORF - Enterprise Value
- balance sheet net asset value indicators:
Book Value of One Share Morphic|MORF - Book Capitalization|Market Capitalization to Book Value morphictx.com|MORF - Cumulative Company Assets
- debt and solvency information:
Aggregate Debt to Capital Morphic Holding, Inc.|MORF - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Morphic Holding Corp|MORF - Company Debts|Debts to Book Value Morphic Therapeutic|MORF - Company Long-Term Debt|Company Short-Term Loans and Borrowings Morphic|Critical Liquidity Ratio morphictx.com
- earnings and multiples data:
MORF - Net Profit|Expected Net Income Morphic Holding, Inc.|MORF - P/E Multiple|Market Cap to Projected Earnings Morphic Therapeutic|MORF - PEG Multiple|Enterprise Value to EBITDA Ratio Morphic Therapeutic|MORF - Operating profit before deduction of amortization|Earnings per share for the trailing year Morphic|MORF - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months morphictx.com|MORF - Earnings per share growth in current year|Expected net earnings per share growth next year Morphic Holding, Inc.
Comprehensive company analysis:MORF (morphictx.com)
Finished products of Morphic Holding, Inc.

The acquisition of Morphic Holding, Inc. (MORF) by the Eli Lilly behemoth radically alters the interpretation of the company's average P/E ratio. This ratio reflects the relationship between market capitalization and net income, measuring the investment payback period. The metric allows for an assessment of business value relative to its ability to generate income. In the context of the merger, the indicator ceases to be risky, as the buyer's resources neutralize R&D uncertainty. Investors should view the current level as a reflection of a strategic premium for access to the biopharmaceutical ecosystem.

Analysis of competing companies

P/E Multiple phathompharma.com|Price to Earnings Ratio TERN (Terns Pharmaceuticals, Inc.)|IRWD (ironwoodpharma.com) - Company Value to Net Income|P/E Multiple CURX (Curanex Pharmaceuticals)|Market Cap to Net Income Ratio Immuron Ltd|Evoke Pharma, Inc. - P/E Multiple|Business Payback Period Entero Therapeutics, Inc. ENTO|RDHL (redhillbio.com) - Price to Earnings Ratio|PALI: Market Price to Net Income Ratio|Price to Earnings Ratio Jaguar Animal Health|Price to Earnings Ratio Biora Therapeutics, Inc (BIOR)